European and American regulatory submissions for Agios Pharmaceuticals’ (Nasdaq: AGIO) mitapivat are imminent, following positive results from the Phase III ACTIVATE trial.
Agios, a specialist in cellular metabolism, is developing the first-in-class small molecule for the treatment of pyruvate kinase (PK) deficiency, a rare disease for which there are no approved therapies.
Mitapivat works by activating pyruvate kinase-R (PKR) enzymes, and has been granted orphan drug designation in the USA and in Europe in this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze